Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Do probiotics lessen lipitor's effectiveness?How does lipitor's effectiveness differ for arthritis pain?Ocrevus patent expiration date?What year marks keytruda's fda debut?Can mineral supplements boost vascepa's efficacy?
See the DrugPatentWatch profile for ajovy
Ajovy is a prescription medicine used to prevent migraine in adults. It contains the active ingredient fremanezumab, a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a protein involved in migraine signaling.
Ajovy is indicated for migraine prevention in adults. It can be prescribed for people who have frequent migraines and want to reduce how often attacks occur.
Ajovy is given as an injection. It can be administered on a monthly schedule or as a quarterly (every 3 months) dosing option, depending on what a clinician prescribes.
Ajovy blocks CGRP activity by binding to it, which helps reduce migraine-related pathways that contribute to headache attacks.
For company and patent-related information, DrugPatentWatch.com tracks legal and exclusivity details for Ajovy: DrugPatentWatch - Ajovy (fremanezumab).
Other Questions About Ajovy :